lamellarin-d has been researched along with Neoplasms* in 3 studies
1 review(s) available for lamellarin-d and Neoplasms
Article | Year |
---|---|
Anticancer properties of lamellarins.
In 1985 the first lamellarins were isolated from a small oceanic sea snail. Today, more than 50 lamellarins have been inventoried and numerous derivatives synthesized and tested as antiviral or anticancer agents. The lead compound in the family is lamellarin D, characterized as a potent inhibitor of both nuclear and mitochondrial topoisomerase I but also capable of directly interfering with mitochondria to trigger cancer cell death. The pharmacology and chemistry of lamellarins are discussed here and the mechanistic portrait of lamellarin D is detailed. Lamellarins frequently serve as a starting point in the design of anticancer compounds. Extensive efforts have been devoted to create novel structures as well as to improve synthetic methods, leading to lamellarins and related pyrrole-derived marine alkaloids. Topics: Animals; Antineoplastic Agents; Cell Death; Coumarins; Drug Design; Heterocyclic Compounds, 4 or More Rings; Humans; Isoquinolines; Mitochondria; Mollusca; Neoplasms; Structure-Activity Relationship | 2015 |
2 other study(ies) available for lamellarin-d and Neoplasms
Article | Year |
---|---|
Another facet to the anticancer response to lamellarin D: induction of cellular senescence through inhibition of topoisomerase I and intracellular Ros production.
Lamellarin D (LamD) is a marine alkaloid with broad spectrum antitumor activities. Multiple intracellular targets of LamD, which affect cancer cell growth and induce apoptosis, have been identified. These include nuclear topoisomerase I, relevant kinases (such as cyclin-dependent kinase 2) and the mitochondrial electron transport chain. While we have previously demonstrated that LamD at micromolar range deploys strong cytotoxicity by inducing mitochondrial apoptosis, mechanisms of its cytostatic effect have not yet been characterized. Here, we demonstrated that induction of cellular senescence (depicted by cell cycle arrest in G2 associated with β-galactosidase activity) is a common response to subtoxic concentrations of LamD. Cellular senescence is observed in a large panel of cancer cells following in vitro or in vivo exposure to LamD. The onset of cellular senescence is dependent on the presence of intact topoisomerase I since topoisomerase I-mutated cells are resistant to senescence induced by LamD. LamD-induced senescence occurs without important loss of telomere integrity. Instead, incubation with LamD results in the production of intracellular reactive oxygen species (ROS), which are critical for senescence as demonstrated by the inhibitory effect of antioxidants. In addition, cancer cells lacking mitochondrial DNA also exhibit cellular senescence upon LamD exposure indicating that LamD can trigger senescence, unlike apoptosis, in the absence of functional mitochondria. Overall, our results identify senescence-associated growth arrest as a powerful effect of LamD and add compelling evidence for the pharmacological interest of lamellarins as potential anticancer agents. Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cellular Senescence; Coumarins; DNA Topoisomerases, Type I; DNA, Mitochondrial; Female; G2 Phase Cell Cycle Checkpoints; Heterocyclic Compounds, 4 or More Rings; Humans; Isoquinolines; Mice, SCID; Mitochondria; Neoplasms; Reactive Oxygen Species; Telomere; Topoisomerase Inhibitors | 2014 |
Essential role of mitochondria in apoptosis of cancer cells induced by the marine alkaloid Lamellarin D.
Lamellarin D, a potent cytotoxic marine alkaloid, exerts its antitumor action through two complementary pathways: a nuclear route via topoisomerase I inhibition and a mitochondrial targeting. The present study was designed to investigate the contribution of these two pathways for apoptosis in cancer cells. Lamellarin D promoted nuclear apoptosis in leukemia cells without prominent cell cycle arrest. Signals transmitted by lamellarin D initiated apoptosis via the intrinsic apoptotic pathway. The drug induced conformational activation of Bax and decreased the expression levels of antiapoptotic proteins Bcl-2 and cIAP2 in association with activation of caspase-9 and caspase-3. Upon lamellarin D exposure, Fas and Fas-L expression was not modified in leukemia cells. Moreover, leukemia cells deficient in caspase-8 or Fas-associated protein with death domain underwent apoptosis through the typical mitochondrial apoptotic cascade, indicating that cell death induced by lamellarin D was independent of the extrinsic apoptotic pathway. Lamellarin D also exerted a topoisomerase I-mediated DNA damage response resulting in H2AX phosphorylation, and the upregulation of the DNA repair protein Rad51 and of p53, as well as the phosphorylation of p53 at serine 15. However, lamellarin D killed efficiently mutated p53 or p53 null cancer cells, and sensitivity to lamellarin D was abrogated neither by cycloheximide nor in enucleated cells. Lamellarin D-induced cytochrome c release occurs independently of nuclear factors in a cell-free system. These results suggest that lamellarin D exerts its cytotoxic effects primarily by inducing mitochondrial apoptosis independently of nuclear signaling. Thus, lamellarin D constitutes a new proapoptotic agent that may bypass certain forms of apoptosis resistance that occur in tumor cells. Topics: Animals; Apoptosis; Baculoviral IAP Repeat-Containing 3 Protein; bcl-2-Associated X Protein; Caspase 3; Caspase 9; Cell Cycle; Cell Line, Tumor; Coumarins; DNA Damage; DNA Topoisomerases, Type I; Flow Cytometry; HCT116 Cells; Heterocyclic Compounds, 4 or More Rings; Histones; Humans; Immunoblotting; Inhibitor of Apoptosis Proteins; Isoquinolines; Jurkat Cells; Microscopy, Fluorescence; Mitochondria; Mutation; Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Tumor Suppressor Protein p53; Ubiquitin-Protein Ligases | 2009 |